News

New publication in Research and Practice in Thrombosis and Haemostasis “COVID-19 Pandemic Perspectives:  A Scientific Silver Lining?” Abstract Accounts of the numerous negative effects caused by COVID‐19 are pervasive, but few perspectives have identified any positive impacts of this massive societal shift. This forum examines potentially positive changes that have occurred within the scientific community …

Read more

  Link to view presentation

Read more

Factor XIII Deficiency Does Not Prevent FeCl3-induced Carotid Artery Thrombus Formation in Mice Background: The compositions of venous (red blood cell-rich) and arterial (platelet-rich) thrombi are mediated by distinct pathophysiologic processes; however, fibrin is a major structural component of both. The transglutaminase factor XIII (FXIII) stabilizes fibrin against mechanical and biochemical disruption and promotes red …

Read more

A high-fat diet delays plasmin generation in a thrombomodulin-dependent manner in mice Obesity is a prevalent prothrombotic risk factor marked by enhanced fibrin formation and suppressed fibrinolysis. Fibrin both promotes thrombotic events and drives obesity pathophysiology, but a lack of essential analytical tools has left fibrinolytic mechanisms affected by obesity poorly defined. Using a plasmin-specific …

Read more

The factor XIII‐A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations Background: Factor XIII (FXIII) promotes fibrin crosslinking and red blood cell (RBC) retention in clots. The FXIII‐A polymorphism, Val34Leu, is associated with protection against venous thrombosis. This effect is hypothesized to result from fibrinogen concentration‐dependent changes in fibrin structure. Effects of the …

Read more

Wonderful presentation Friday by Anna Silver at the BIOL 395 Research Poster Symposium!

Read more

Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α‐chain crosslinking Background: Hemophilia A results from the absence, deficiency or inhibition of factor VIII . Bleeding is treated with hemostatic agents (FVIII , recombinant activated FVII [rFVII a], anti‐inhibitor coagulation complex [FEIBA ], or recombinant porcine FVIII [rpFVIII ]). Despite treatment, some patients …

Read more

Spotlight on “Red blood cells in thrombosis” now in print! Read it here.

Read more

A new review titled “Red blood cells in thrombosis” (Byrnes and Wolberg) has been published in Blood. Read the abstract here.

Read more

Congratulations to Jamie Byrnes and Sravya Kattula for outstanding talks at the ISTH Congress in Berlin, Germany!

Read more